Cigna Investments Inc. New Lowers Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Cigna Investments Inc. New cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 0.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,111 shares of the medical research company’s stock after selling 23 shares during the quarter. Cigna Investments Inc. New’s holdings in Thermo Fisher Scientific were worth $2,182,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of TMO. Halpern Financial Inc. increased its holdings in shares of Thermo Fisher Scientific by 307.7% during the third quarter. Halpern Financial Inc. now owns 53 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 40 shares in the last quarter. Coppell Advisory Solutions LLC bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at $33,000. Live Oak Investment Partners bought a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $36,000. Tyler Stone Wealth Management purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at $37,000. Finally, Indiana Trust & Investment Management CO purchased a new stake in shares of Thermo Fisher Scientific during the third quarter worth about $38,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Royal Bank of Canada increased their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Robert W. Baird reaffirmed an “outperform” rating and issued a $670.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, December 14th. TheStreet raised Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research report on Friday, December 22nd. HSBC initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, December 18th. They set a “buy” rating and a $610.00 price objective on the stock. Finally, Citigroup assumed coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 target price for the company. Five research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $599.00.

Read Our Latest Stock Report on TMO

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the sale, the chief executive officer now owns 49,155 shares in the company, valued at $27,311,992.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the transaction, the chief executive officer now directly owns 49,155 shares in the company, valued at approximately $27,311,992.65. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock worth $28,513,384 over the last three months. 0.32% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Down 1.5 %

Shares of NYSE:TMO traded down $8.85 during trading on Tuesday, reaching $568.60. The stock had a trading volume of 213,992 shares, compared to its average volume of 1,583,860. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $216.81 billion, a P/E ratio of 37.39, a PEG ratio of 2.44 and a beta of 0.80. The firm’s 50-day simple moving average is $566.95 and its 200 day simple moving average is $521.68. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last issued its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. During the same quarter in the prior year, the business posted $5.40 EPS. The business’s revenue for the quarter was down 4.9% compared to the same quarter last year. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 15th will be paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date of this dividend is Thursday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is presently 10.10%.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Further Reading

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.